Corcept Therapeutics to Present Data at the 2019 American Association of Clinical Endocrinologists’ 28th Annual Congress
Data presented will include an oral and poster presentation on
Thursday, April 25th | |
Improvement in Muscle Strength and Psychiatric Symptoms in a Patient with Persistent Cushing Disease Treated with Mifepristone T. Yacoub; K. Palaniswamy |
e-Poster Presentation Time: 1:00 - 1:30 pm Monitor Number: 34 |
Mifepristone Provides Beneficial Clinical Improvement in Two Cushing Disease Cases in a Community Endocrinology Practice C. Iweha; D. Chavez |
e-Poster Presentation Time: 1:30 - 2:00 pm Monitor Number: 1 |
Clinical Consequences of an Untreated Cortisol- Producing Adrenal Adenoma: A 10-Year History T. Jerkins; R. Jerkins; R. Ray |
e-Poster Presentation Time: 1:00 - 1:30 pm Monitor Number: 17 |
Prevalence of Hypercortisolism in Patients with Type 2 Diabetes Mellitus with Incidentally Found Adrenal Adenomas: An Interim Analysis I. Sachmechi; M. Alkomos; P. Zarghamravanbakhsh; R. Mahendhar; K. Palaniswamy |
e-Poster Presentation Time: 1:30 - 2:00 pm Monitor Number: 9 |
Saturday, April 27th | |
Efficacy and Safety of the Selective Glucocorticoid Receptor Modulator, Relacorilant (up to 400 mg/day), in Patients with Endogenous Hypercortisolism: Results from an Open-Label Phase 2 Study R. Pivonello; A. Kargi; N. Ellison; A. Moraitis; M. Terzolo |
Oral Poster Presentation Time: 10:15 - 10:30 am Location: Petree Hall |
Hypercortisolism
Hypercortisolism, often referred to as Cushing’s syndrome, is caused by excessive activity of the hormone cortisol. Endogenous Cushing’s syndrome is an orphan disease that most often affects adults aged 20-50. In
About
Corcept is a commercial-stage company engaged in the discovery and development of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Corcept’s approved product, Korlym®, was the first
CONTACT:
Director, Investor Relations
650-684-8725
cjames@corcept.com
www.corcept.com
Source: Corcept Therapeutics Incorporated